Androgen receptor antagonist 10
Androgen receptor antagonist 10 (compound 6h) is a androgen receptor antagonist. Androgen receptor antagonist 10 reduces the wax esters in the golden syrian hamster model.
For research use only. We do not sell to patients.
- CAS No.: 876759-87-4
- Formula: C15H10F3NOS
- Molecular Weight:309.31
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-231 | IC50 |
22 nM
Compound: 6h
|
Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response
Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response
|
[PMID: 19286380] |
| Sf9 | IC50 |
74 nM
Compound: 6h
|
Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system
Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system
|
[PMID: 19286380] |
Chemical Information
-
CAS No. 876759-87-4
-
Molecular Weight 309.31
-
Formula C15H10F3NOS
-
SMILES
CSC1=CC=CC=C1OC2=CC(C(F)(F)F)=C(C#N)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Androgen receptor antagonist 10 Related Classifications
HY-160659 Related Classifications
Powered by Bioz